July 24 (Reuters) – A panel of outside advisers to the U.S. FDA on Friday voted to exclude peptide emideltide from a list that would allow broader pharmacy compounding.
Seven members voted against recommending emideltide to be on the list, while six members voted in favor. One member abstained.
(Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
